These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 30343173)
1. Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. Edwards P; Davidson M; Calamai V; Cunningham D; Starling N Cancer Treat Rev; 2018 Dec; 71():32-38. PubMed ID: 30343173 [TBL] [Abstract][Full Text] [Related]
2. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492 [TBL] [Abstract][Full Text] [Related]
3. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. Davidson M; Chau I Expert Rev Anticancer Ther; 2018 Apr; 18(4):327-338. PubMed ID: 29431018 [TBL] [Abstract][Full Text] [Related]
4. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. Petrelli F; Tomasello G; Barni S Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for oesophagogastric cancer. Davidson M; Chau I Expert Opin Biol Ther; 2016 Oct; 16(10):1197-207. PubMed ID: 27409159 [TBL] [Abstract][Full Text] [Related]
8. [Strategies around PD-L1 testing in France]. Penault-Llorca F Ann Pathol; 2017 Feb; 37(1):3-4. PubMed ID: 28108043 [No Abstract] [Full Text] [Related]
9. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study. Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568 [TBL] [Abstract][Full Text] [Related]
10. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge? Al-Batran SE; Lorenzen S Hematol Oncol Clin North Am; 2017 Jun; 31(3):441-452. PubMed ID: 28501086 [TBL] [Abstract][Full Text] [Related]
11. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M; Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827 [TBL] [Abstract][Full Text] [Related]
12. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. De Mello RA; Lordick F; Muro K; Janjigian YY Am Soc Clin Oncol Educ Book; 2019 Jan; 39():237-247. PubMed ID: 31099644 [TBL] [Abstract][Full Text] [Related]
13. [Progression of immunotherapy in gastric cancer]. Wei X; Xu R Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889 [TBL] [Abstract][Full Text] [Related]